Sign In
Buy APVO
$4.11
-0.0200 (-0.484%)
At Close: Jul 31, 2026
The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
11:32am, Friday, 04'th Oct 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thu
Aptevo Therapeutics Provides Corporate and Pipeline Update
08:02pm, Thursday, 03'rd Oct 2019
During the third quarter of 2019 revenue for IXINITY continued to increase. Preliminary net product sales of IXINITY during the third quarter of 2019 are approximately $9 million compared to $5.8 mi
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
01:00pm, Thursday, 19'th Sep 2019
New ADAPTIR Candidate APVO603 is a Dual-Agonistic BispecificAntibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responseswith.
Aptevo Therapeutics Reports Second Quarter 2019 Financial Results
01:00pm, Friday, 09'th Aug 2019
Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD).
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited
01:02pm, Wednesday, 07'th Aug 2019
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol Int
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials
08:32pm, Thursday, 25'th Jul 2019
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has completed dosing in a single ascendin
